Gilead Sciences Portfolio holdings
Gilead Sciences is an American biopharmaceutical company that researches and develops antiviral drugs for HIV/AIDS, hepatitis B and C, influenza and COVID-19. Michael Riordan, a doctor who was then an associate at the venture firm Menlo Ventures, founded it in 1987 as Oligogen, a name pointing to oligonucleotides, small strands of DNA. Riordan used Oligogen only while clearing a trademark issue with a California nonprofit, and he took the Gilead name from the Balm of Gilead, which he first met in a Lanford Wilson play. Gilead discovered the flu drug Tamiflu and licensed it to Roche, and its 2011 purchase of Pharmasset brought it sofosbuvir, approved in 2013 as the hepatitis C treatment Sovaldi. In 2017 Gilead said it would acquire Kite Pharma as its entry into cell therapy, a deal that had produced two lymphoma treatments, Yescarta and Tecartus, by 2022.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Assembly Biosciences
ASMB
|
+$12.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arcellx
ACLX
|
+$772M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Arcus Biosciences
RCUS
$2.37B
| $969M | 58.76% |
31,424,760
| – | – |
2024 Q4
6 quarters
|
|
2
Lakefront Biotherapeutics American Depositary Shares
LKFT
$2.13B
| $500M | 30.34% |
16,707,477
| – | – |
2024 Q4
6 quarters
|
|
|
3
Assembly Biosciences
ASMB
$425M
| $137M | 8.3% |
4,977,089
+471,698
| +10% | +$12.8M |
2024 Q4
6 quarters
|
|
4
Kyverna Therapeutics
KYTX
$362M
| $36.8M | 2.23% |
4,126,119
| – | – |
2024 Q4
6 quarters
|
|
5
Xilio Therapeutics
XLO
$51.1M
| $6.23M | 0.38% |
650,389
| – | – |
2024 Q4
6 quarters
|
|
|
6
DELISTED
Arcellx
ACLX
| – | – |
-6,720,803
| Closed | -$772M | – |
|
Similar funds
Gilead Sciences's Q2 2026 Portfolio in Review
As of Q2 2026, Gilead Sciences held 6 positions worth $1.65B, down 22% from $2.12B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Gilead Sciences withdrew a net $759M in Q2 2026, closing 1 position. Its most notable exit was Arcellx, an estimated $772M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Gilead Sciences added an estimated $12.8M to Assembly Biosciences.
- Gilead Sciences added most to Assembly Biosciences in Q2 2026, an estimated $12.8M increase.
- Gilead Sciences fully exited Arcellx in Q2 2026, selling an estimated $772M.
- Gilead Sciences's ten largest holdings make up 100% of its $1.65B portfolio in Q2 2026.
- Gilead Sciences opened 0 new positions and closed 1 in Q2 2026.
- Gilead Sciences's portfolio value fell 22% quarter-over-quarter to $1.65B.
Based on Gilead Sciences's 13F filing for Q2 2026, filed 3 Aug 2026.